ROCKVILLE, Md., March 18, 2024 /PRNewswire/ -- Psomagen Inc., with the support of the Global Parkinson's Genetics Program (GP2), will perform whole genome sequencing (WGS) on a global cohort of 80,000 patients and research participants to execute GP2's aim to use genetic knowledge to accelerate the path to the development and deployment of therapeutic strategies for Parkinson's Disease (PD).

马里兰州罗克维尔。，2024年3月18日，在全球帕金森病遗传学计划（GP2）的支持下，Psomagen Inc.将对全球80000名患者和研究参与者进行全基因组测序（WGS），以执行GP2的目标，即利用遗传知识加速帕金森病（PD）治疗策略的开发和部署。

The program will run over the next 2.5 - 3 years using Illumina sequencing instruments and reagents.

该计划将使用Illumina测序仪器和试剂在未来2.5-3年内运行。

GP2 is a program supported by the Aligning Science Across Parkinson's (ASAP) initiative managed by the Coalition for Aligning Science and implemented by The Michael J. Fox Foundation for Parkinson's Research (MJFF) and is focused on improving our understanding of the genetic architecture of Parkinson's disease and making this knowledge globally relevant.

GP2是由对齐科学联盟（Aligning Science for Aligning Science）管理并由迈克尔·福克斯帕金森研究基金会（MJFF）实施的“跨越帕金森氏症的对齐科学”（ASAP）倡议支持的一个项目，旨在提高我们对帕金森氏病遗传结构的理解，并使这些知识具有全球相关性。

The program is made up of member organizations and over 160 cohorts collecting samples and data from around the world to create a global research community dedicated to rapidly addressing emerging research needs in PD. GP2 specifically has the goal of including groups traditionally underrepresented in genetics research, to diversify its understanding of PD by focusing on inclusion in the research pipeline.

该计划由成员组织和160多个队列组成，从世界各地收集样本和数据，以创建一个全球研究社区，致力于快速解决PD中新兴的研究需求。GP2的具体目标是将传统上在遗传学研究中代表性不足的群体包括在内，通过专注于纳入研究渠道，使其对PD的理解多样化。

The global initiative is led by Andrew Singleton, PhD and Cornelis Blauwendraat, PhD of the National Institutes of Health. GP2 cohort samples will start to be processed immediately.

全球倡议由美国国立卫生研究院安德鲁·辛格尔顿博士和科内利斯·布劳文德拉博士领导。GP2队列样本将立即开始处理。

'Our collaboration with Psomagen Inc. is an important step towards ASAP's vision of improving processes that deliver faster and better outcomes for PD,' said Ekemini Riley, PhD, managing director at ASAP. 'Diverse cohort samples collected by GP2 from all over the world will be processed and analyzed to generate whole genome sequencing data that can detect new variants, address gaps in our knowledge of PD, and improve the understanding of the disease.'

ASAP董事总经理EkeminiRiley博士说，我们与Psomagen Inc.的合作是朝着ASAP的愿景迈出的重要一步，即改进流程，为PD提供更快更好的结果GP2从世界各地收集的不同队列样本将进行处理和分析，以生成全基因组测序数据，这些数据可以检测新的变异，解决我们对PD知识的差距，并提高对疾病的理解。”

U.S. multi-omics contract research organization, Psomagen Inc. (KOSDAQ 950200), will perform the human whole genome sequencing at their laboratories and headquarters located in Rockville, MD.  Matt Kramer, V.P. of Sales & Marketing at Psomagen, stated, 'With our nearly 20 years of services experience, the key to our customers' success has been built on trust of our customers through continued collaborations like our work with the GP2 program.  Maintaining a high service level comes from our attention to detail and accurate results with our CLIA approved, CAP accredited, and ISO certified labs - consistently meeting the requirements of such national and/or global-scale projects.

U、 美国多组学合同研究组织Psomagen Inc.（KOSDAQ 950200）将在位于马里兰州罗克维尔的实验室和总部进行人类全基因组测序。Psomagen销售与营销副总裁马特·克莱默表示，“凭借我们近20年的服务经验，客户成功的关键是通过持续的合作，如我们与GP2计划的合作，建立在客户的信任之上。保持高服务水平源于我们通过CLIA批准、CAP认证和ISO认证的实验室对细节和准确结果的关注-始终满足此类国家和/或全球规模项目的要求。

It's our honor to serve the mission of ASAP and work with GP2 and The Michael J. Fox Foundation in this incredible effort.'

我们很荣幸能够为ASAP的使命服务，并与GP2和迈克尔·福克斯基金会（MichaelJ.Fox Foundation）在这项难以置信的努力中合作。”

Psomagen will utilize the NovaSeq X Plus, Illumina's most powerful high-throughput sequencer, with its 25B flow cell, library preparation kits and analysis software to generate the whole-genome sequencing data.

Psomagen将利用NovaSeq X Plus（Illumina最强大的高通量测序仪）及其25B流通池，文库制备试剂盒和分析软件来生成全基因组测序数据。

'An initiative to sequence and analyze 80,000 whole genomes in this timeframe would not have been possible even 5-10 years ago, so we are really excited that the NovaSeq X Plus will help enable this critical work to advance our understanding of PD,' said Nicole Berry, Head of Americas Region, Illumina.

Illumina美洲地区负责人妮可·贝里（NicoleBerry）说：“即使在5-10年前，在这个时间范围内对80000个全基因组进行测序和分析的倡议也是不可能的，因此我们非常高兴NovaSeq X Plus将有助于这项关键工作，以增进我们对PD的理解。”

'And the global cohort built by GP2 will serve to improve the diversity of genomic data that will ultimately inform improved precision therapies for more people with PD around the world.'

“由GP2建立的全球队列将有助于改善基因组数据的多样性，最终为全世界更多PD患者提供改进的精确疗法。”

About Psomagen Inc.

关于Psomagen Inc。

Psomagen, formerly Macrogen, is a Contract Research Services (CRO) provider celebrating its 20th year anniversary in 2024 – over this time it has offered genomic, transcriptomic, and proteomic analysis to research programs and operations throughout North America, serving academic, pharma, biotech, government and industry.  Its US-based, CAP and CLIA certified laboratories are located in Rockville, MD, New York City, NY and Boston, MA and provide genomics, transcriptomics and proteomics technologies such as short and long-read next-generation sequencing (NGS), Sanger (CE) sequencing, microarray, single-cell omics, metagenomics and microbiome, spatial biology, bioinformatics and biomarker discovery.  Psomagen utilizes state-of-the-art technology from partners such as Illumina, 10X Genomics, and PacBio among others, providing services including nucleic acid or protein extraction, sample quality control, assay preparation, analysis and interpretation.

Psomagen，原名Macrogen，是一家合同研究服务（CRO）提供商，于2024年庆祝其成立20周年。在此期间，它为整个北美的研究项目和运营提供基因组学、转录组学和蛋白质组学分析，服务于学术界、制药界、生物技术界、政府和行业。其美国CAP和CLIA认证实验室位于马里兰州罗克维尔，纽约州纽约市和马萨诸塞州波士顿，提供基因组学，转录组学和蛋白质组学技术，如短读和长读下一代测序（NGS），桑格（CE）测序，微阵列，单细胞组学，宏基因组学和微生物组学，空间生物学，生物信息学和生物标志物发现。Psomagen利用Illumina、10X Genomics和PacBio等合作伙伴的最新技术，提供核酸或蛋白质提取、样品质量控制、测定制备、分析和解释等服务。

About Aligning Science Across Parkinson's (ASAP)

关于将科学与帕金森氏症联系起来（ASAP）

Aligning Science Across Parkinson's is a coordinated research initiative dedicated to accelerating the pace of discovery and informing the path to a cure for Parkinson's disease (PD) through collaboration, the generation of research-enabling resources, and data sharing. ASAP supports five major programs, including the Global Parkinson's Genetics Program which aims to improve the understanding of genetic architecture of PD by integrating ancestrally diverse populations to address gasps in knowledge about the disease and make PD genetics globally relevant.

协调帕金森氏病的科学是一项协调一致的研究计划，旨在通过合作、产生研究支持资源和数据共享，加快发现速度，为帕金森氏病（PD）的治疗提供信息。ASAP支持五个主要项目，包括全球帕金森氏症遗传学计划，该计划旨在通过整合祖先不同的人群来解决有关该疾病的知识不足并使PD遗传学具有全球相关性，从而提高对PD遗传结构的理解。